Seeking solutions

We focus on diseases with great unmet medical need such as:

alzheimer’s disease - affecting approximately 24 million people worldwide today and possibly 40 million by 2020. The key pathophysiological step seems be amyloid build-up in the brain; reducing or removing it could alleviate the symptoms and stop disease progression.

cancer - remains the second highest cause of death in developed countries and accounts for 7.6 million of all deaths worldwide annually. Our oncology pipeline includes both small molecules and biologics that target the signalling pathways believed to be pivotal in cancer cell growth, invasion, and survival, including cell division and the growth of new blood vessels.

type 2 diabetes - health authorities around the world are increasingly concerned about the rapid rise in the incidence and prevalence of type 2 diabetes and obesity, which are major risk factors for cardiovascular morbidity and mortality.

In collaboration with R&D partners, we are developing agents with profiles that reflect the close interrelationship between these two diseases.

chronic obstructive pulmonary disease (COPD) - currently, the fifth leading cause of death in the world, estimated to affect over 200 million people. Our early pipeline is strong, combining oral compounds, inhaled compounds and antibodies.

infection - demand for anti-microbial agents remains high due to escalating bacterial resistance, limitations of available antiviral agents, and the increased risk of serious infections in both immunosuppressed patients and ageing populations. We are well positioned to exploit our structural and genomic-based discovery technologies and our antibody platforms.